Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. National Heart and Lung Institute
  4. National Heart and Lung Institute
  5. TLR1/2 and 5 induce elevated cytokine levels from rheumatoid arthritis monocytes independent of ACPA or RF autoantibody status.
 
  • Details
TLR1/2 and 5 induce elevated cytokine levels from rheumatoid arthritis monocytes independent of ACPA or RF autoantibody status.
File(s)
keaa220.pdf (283.07 KB)
Published version
OA Location
https://academic.oup.com/rheumatology/article/doi/10.1093/rheumatology/keaa220/5864219
Author(s)
Thwaites, Ryan S
Unterberger, Sarah
Chamberlain, Giselle
Walker-Bone, Karen
Davies, Kevin A
more
Type
Journal Article
Abstract
OBJECTIVE: RA is an autoimmune inflammatory joint disease. Both RF and ACPA are associated with more progressive disease and higher levels of systemic inflammation. Monocyte activation of toll-like receptors (TLRs) by endogenous ligands is a potential source of increased production of systemic cytokines. RA monocytes have elevated TLRs, some of which are associated with the disease activity score using 28 joints (DAS28). The aim of this study was to measure TLR-induced cytokine production from monocytes, stratified by autoantibody status, to assess if their capacity to induce cytokines is related to autoantibody status or DAS28. METHODS: Peripheral blood monocytes isolated from RA patients and healthy controls were stimulated with TLR1/2, TLR2/6, TLR4, TLR5, TLR7, TLR8 and TLR9 ligands for 18 h before measuring IL-6, TNFα and IL-10. Serum was used to confirm the autoantibody status. Cytokine levels were compared with RF, ACPA and DAS28. RESULTS: RA monocytes demonstrated significantly increased IL-6 and TNFα upon TLR1/2 stimulation and IL-6 and IL-10 upon TLR5 activation. TLR7 and TLR9 activation did not induce cytokines and no significant differences were observed between RA and healthy control monocytes upon TLR2/6, TLR4 or TLR8 activation. When stratified by ACPA or RF status there were no correlations between autoantibody status and elevated cytokine levels. However, TLR1/2-induced IL-6 did correlate with DAS28. CONCLUSIONS: Elevated TLR-induced cytokines in RA monocytes were not related to ACPA or RF status. However, TLR1/2-induced IL-6 was associated with disease activity.
Date Issued
2020-11
Date Acceptance
2020-06-01
Citation
Rheumatology, 2020, 59 (11), pp.3533-3539
URI
http://hdl.handle.net/10044/1/80698
URL
https://academic.oup.com/rheumatology/article/doi/10.1093/rheumatology/keaa220/5864219
DOI
https://www.dx.doi.org/10.1093/rheumatology/keaa220
ISSN
1462-0324
Publisher
British Society for Rheumatology
Start Page
3533
End Page
3539
Journal / Book Title
Rheumatology
Volume
59
Issue
11
Copyright Statement
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
http://creativecommons.org/licenses/by/4.0/
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32594150
PII: 5864219
Subjects
ACPA
DAS28
RF
TNFα
interleukin-10
interleukin-6
rheumatoid arthritis
toll-like receptor
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2020-06-28
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback